RxSight Q3 revenue up 76% to $22.2M; raises FY2023 guidance

RxSight, Inc.

2023-Q3 EPS reported -$1.16 revenue$60,497,000

Q3 revenue $22.2M (+76% YoY); net loss $(12.4)M, EPS $(0.35); adjusted net loss $(6.9)M, adj. EPS $(0.19)
Sold 66 LDDs (installed base 589, +72% YoY); LAL procedure volumes 13,657 (+107% YoY)
Raised FY2023 revenue guidance to $85-87M (prior $81-86M); gross margin guidance 60-61% (prior 58-60%)
Eliminated remaining $20M term loan; expects to reduce annualized interest expense by ~$5.6M
Raised $11.7M net via ATM facility; cash/short-term investments $131.9M at quarter end

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

RxSight, Inc. reported three and nine months ended September 30, 2023 results: revenue $22.2 million, net income $(12.4) million, EPS $(0.35) per basic and diluted share. Guidance raised.

Period: three and nine months ended September 30, 2023
Revenue: $22.2 million
Net income: $(12.4) million
EPS: $(0.35) per basic and diluted share
Guidance: raised
Result: reported results

Exact text from the filing

cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights • Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: • The sale of 66 Light Delivery Devices (LDDTMs), representing a 35% increase in unit sales compared to the

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.